Ontology type: schema:ScholarlyArticle Open Access: True
2006-12
AUTHORSAmit Agrawal, John F R Robertson, K L Cheung
ABSTRACTBACKGROUND: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs ("ethinylestradiol" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents. PATIENTS AND METHODS: According to a database of advanced breast cancer patients seen in our Unit since 1998, those who had complete set of information and fulfilled the following criteria were studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was assessable by UICC criteria; (3) were treated with "ethinylestradiol" until they were withdrawn from treatment due to adverse events or disease progression. RESULTS: Twelve patients with a median age of 75.1 years (49.1-85 years) were identified. Majority (N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient (8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response or durable stable disease for > or = 6 months) was seen in 4 patients (33.3%) with a median duration of response of 10+ (7-36) months. The time to treatment failure was 4 (0.5-36) months. CONCLUSION: Yet unreported, high dose "ethinylestradiol" is another viable therapeutic strategy in heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it tends to carry more side effects, they may not be comparable to those of other HDEs (such as diethylstilbestrol) or chemotherapy. More... »
PAGES44
http://scigraph.springernature.com/pub.10.1186/1477-7819-4-44
DOIhttp://dx.doi.org/10.1186/1477-7819-4-44
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1033917230
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/16834778
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Agrawal",
"givenName": "Amit",
"id": "sg:person.01036236301.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036236301.85"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Robertson",
"givenName": "John F R",
"id": "sg:person.07764637207.20",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Professorial Unit of Surgery, City Hospital, University of Nottingham, NG5 1PB, Nottingham, UK"
],
"type": "Organization"
},
"familyName": "Cheung",
"givenName": "K L",
"id": "sg:person.016477423232.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016477423232.32"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1023/a:1006185805079",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1000717306",
"https://doi.org/10.1023/a:1006185805079"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.breast.2005.08.022",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001017334"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.breast.2005.08.022",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1001017334"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0140-6736(74)91364-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006753414"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1186/bcr436",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1010302564",
"https://doi.org/10.1186/bcr436"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011360956"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1023/a:1010619225209",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1011725288",
"https://doi.org/10.1023/a:1010619225209"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.ejca.2004.07.035",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1027051769"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/s0959-8049(97)00178-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1030310702"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1971.33",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033932369",
"https://doi.org/10.1038/bjc.1971.33"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/bjc.1971.33",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1033932369",
"https://doi.org/10.1038/bjc.1971.33"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejm198101013040104",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037574283"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1016/j.jsbmb.2004.12.005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1050101750"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1136/bmj.2.5973.711",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051594563"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1210/jcem.80.10.7559875",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064319145"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1074641688",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1082226833",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1082233451",
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1082983068",
"type": "CreativeWork"
}
],
"datePublished": "2006-12",
"datePublishedReg": "2006-12-01",
"description": "BACKGROUND: High dose estrogens (HDEs) were frequently used as endocrine agents prior to the introduction of tamoxifen which carries fewer side effects. Due to the development of resistance to available endocrine agents in almost all women with metastatic breast cancer, interest has renewed in the use of HDEs as yet another endocrine option that may have activity. We report our experience with one of the HDEs (\"ethinylestradiol\" 1 mg daily) in advanced breast cancer (locally advanced and metastatic) in post-menopausal women who had progressed on multiple endocrine agents.\nPATIENTS AND METHODS: According to a database of advanced breast cancer patients seen in our Unit since 1998, those who had complete set of information and fulfilled the following criteria were studied: (1) patients in whom further endocrine therapy was deemed appropriate i.e., patients who have had clinical benefit with previous endocrine agents or were not fit or unwilling to receive chemotherapy in the presence of potentially life-threatening visceral metastases; (2) disease was assessable by UICC criteria; (3) were treated with \"ethinylestradiol\" until they were withdrawn from treatment due to adverse events or disease progression.\nRESULTS: Twelve patients with a median age of 75.1 years (49.1-85 years) were identified. Majority (N = 8) had bony disease. They had ethinylestradiol as 3rd to 7th line endocrine therapy. One patient (8%) came off treatment early due to hepato-renal syndrome. Clinical benefit (objective response or durable stable disease for > or = 6 months) was seen in 4 patients (33.3%) with a median duration of response of 10+ (7-36) months. The time to treatment failure was 4 (0.5-36) months.\nCONCLUSION: Yet unreported, high dose \"ethinylestradiol\" is another viable therapeutic strategy in heavily pre-treated patients when further endocrine therapy is deemed appropriate. Although it tends to carry more side effects, they may not be comparable to those of other HDEs (such as diethylstilbestrol) or chemotherapy.",
"genre": "research_article",
"id": "sg:pub.10.1186/1477-7819-4-44",
"inLanguage": [
"en"
],
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1032056",
"issn": [
"1477-7819"
],
"name": "World Journal of Surgical Oncology",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "4"
}
],
"name": "Efficacy and tolerability of high dose \"ethinylestradiol\" in post-menopausal advanced breast cancer patients heavily pre-treated with endocrine agents",
"pagination": "44",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"a1927426a4d4d0ba207692d379659f5b353fa2f11e423d1eb64ab61c8b93399c"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"16834778"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101170544"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/1477-7819-4-44"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1033917230"
]
}
],
"sameAs": [
"https://doi.org/10.1186/1477-7819-4-44",
"https://app.dimensions.ai/details/publication/pub.1033917230"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-10T18:21",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8675_00000514.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1186%2F1477-7819-4-44"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/1477-7819-4-44'
This table displays all metadata directly associated to this object as RDF triples.
136 TRIPLES
21 PREDICATES
46 URIs
21 LITERALS
9 BLANK NODES